SAI MedPartners Acquires PharmaForce


READING, Pa.–(BUSINESS WIRE)–SAI MedPartners (“SAI”), a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce it has acquired PharmaForce International (“PharmaForce”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022.

“We are delighted to welcome PharmaForce to the SAI family, further enhancing our competitive intelligence capabilities. PharmaForce’s commercial benchmarking offerings complement our core CI services by providing supplemental data and incremental insights to our customers,”

Erik Nordhoy, Founder and CEO of SAI

PharmaForce, headquartered in Reading, PA, is a market intelligence firm that focuses on analyzing the sales, marketing, market access, and medical affairs activities of leading pharmaceutical and biotech companies primarily through syndicated research reports. PharmaForce’s offerings allow its clients to better understand the commercial operations of their competitors, enabling enhanced strategic decision-making. The PharmaForce team will constitute SAI’s Syndicated Offering division.

Greg Yoder, COO of PharmaForce, commented “We are very excited to be joining the SAI team. We look forward to continuing to provide CI services to our client base, while expanding our reach and breadth of offerings through the existing SAI network and platform.”

ABOUT SAI MEDPARTNERS

SAI is a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Reading, Pennsylvania, SAI provides best-in-class competitive intelligence and strategy support services to assist its clients across the product development lifecycle. SAI works with leading multinational pharmaceutical companies, in addition to a growing number of biotechnology and medical device companies. SAI has a presence across the United States, Europe, and Asia. For more information, please visit www.sai-med.com.

ABOUT NORTHLANE CAPITAL PARTNERS

Based in Bethesda, MD, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested more than $1.6 billion of equity capital. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value. For more information, please visit www.northlanecapital.com.

Source: https://www.businesswire.com/news/home/20230329005633/en/SAI-MedPartners-Acquires-PharmaForce


Similar posts:

By Maren Nordhoy on January 25, 2023

It is no secret that social media is an essential channel for expressing opinions and sharing facts. Depicted through visual representations and the written word, the world works fundamentally through online channels, without which we would be thrown back into a rudimentary and non-progressive lifestyle.  

By Helena Mello, PhD on September 19, 2022

There are over 7,000 rare diseases described, affecting about 20-30 million people in the U.S. alone, according to the NIH. While each condition has its specificities, there are common challenges in the rare disease space, such as finding patients and leveraging centers of excellence and referral networks. This article discusses such challenges and how partnering with SAI’s subject matter experts can help overcome them.

By Helena Mello, PhD on August 31, 2022

Medical conference coverage requires both knowledge of the therapeutic area and the ability to synthesize key points from several individual sessions into nuanced, meaningful intelligence. At SAI, we compile the pertinent data presented at the conference, provide key takeaways from relevant presentations, and include meaningful summaries coupled with insights from KOLs and prominent experts in the field.

Connect with us on LinkedIn for up-to-the-minute insights

Scroll to top